People | May 17, 2024
Takeda appoints Annapurna Das as the General Manager, India Operations
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Investing considerably in production capacity for medical device packaging at its Rohrdorf and Halle sites in Germany
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Before joining Gland, Loomba was associated with Shalina Labs, Harman Finochem, Aurobindo Pharma, Sun Pharmaceuticals and Ranabaxy Laboratories.
Subscribe To Our Newsletter & Stay Updated
